Recently, Henlius, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co.,Ltd., released its 2025 interim results. The company achieved revenue of 2.8195 billion RMB in the first half of 2025, representing a 2.7% year-over-year increase. Gross profit reached approximately 2.1992 billion RMB, up 10.5% year-over-year, with net profit of 390.1 million RMB. Operating cash flow exceeded 770.9 million RMB, surging 206.8% year-over-year and maintaining positive inflows.
Henlius is an international innovative biopharmaceutical company committed to providing affordable, high-quality biologics for patients worldwide. Its product portfolio covers oncology, autoimmune diseases, ophthalmology, and other therapeutic areas. Since its establishment in 2010, Henlius has built an integrated biopharmaceutical platform with efficient and innovative core capabilities spanning the entire industry chain of R&D, manufacturing, and commercial operations. The company has established a comprehensive and efficient global innovation center, conducting production and quality control according to international Good Manufacturing Practice (GMP) standards, continuously strengthening its integrated comprehensive production platform. The company's commercial production facilities have successively obtained GMP certifications from China, the European Union, and the United States.
According to public information, during the reporting period, Henlius's overseas product profits surged over 200%, with BD contract cash inflows exceeding 1 billion RMB, up 280% year-over-year. With the volume growth of overseas commercialized products, the company expects significant growth in overseas product revenue and profits for the full year 2025, with continued high-speed growth anticipated in 2026.
In the first half of 2025, the company's R&D expenses totaled 995.4 million RMB, with expensed R&D spending increasing 21.3% year-over-year, primarily focused on preclinical development of differentiated innovative molecules and construction of core innovation platforms.
Henlius has six products (25 indications) approved for market, including trastuzumab (Hercessi), serplulimab (Hansizhuang), rituximab (Hanlikang), bevacizumab (Hanbeitai), adalimumab (Handayuan), and neratinib maleate (Hannaijia). Four of these products have been approved in various overseas markets, covering nearly 60 countries/regions.
Hercessi is Henlius's independently developed first domestically produced trastuzumab approved in China and its first product commercialized through its own team, launched in the domestic market in August 2020. In the first half, this product achieved sales revenue of approximately 1.4074 billion RMB, an increase of approximately 1.2 million RMB compared to the same period last year. Zercepac® and HERCESSI™ generated overseas sales revenue of approximately 36.8 million RMB.
Hansizhuang is Henlius's first independently developed innovative biologic approved for market, launched domestically in March 2022. In the first half of this year, this product achieved sales revenue of approximately 593.9 million RMB. Zerpidio® and Hetronifly® generated sales revenue of approximately 3.8 million RMB.
Additionally, Hanbeitai generated revenue of 116.3 million RMB in the first half; Hanlikang achieved sales revenue of approximately 274.3 million RMB and licensing revenue of approximately 11 million RMB; Handayuan generated sales revenue of approximately 27.4 million RMB and licensing revenue of approximately 700,000 RMB; Hannaijia achieved sales revenue of approximately 96.8 million RMB.
Currently, Henlius has a research pipeline of approximately 50 molecules and over 10 R&D platforms, covering diverse drug modalities including monoclonal antibodies, multispecific antibodies, antibody-drug conjugates (ADCs), fusion proteins, and small molecule drugs.